Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
Flisiak et al., Pharmacological Reports, doi:10.1007/s43440-022-00408-6 (preprint 7/6/2022)
https://c19early.org/flisiak2.html